Influence of the linker in bispyridium compounds on the inhibition of human choline kinase

Journal of Medicinal Chemistry

Volumn 47, Issue 22, 2004, Pages 5433-5440

  Conejo García, Ana ^b   Báñez Coronel, Mónica ^a   Sañchez Martín, Rosario M ^b   Rodríguez González, Agustín ^a   Ramos, Angeles ^a   De Molina, Ana Ramírez ^a   Espinosa, Antonio ^b   Gallo, Miguel Angel ^b   Campos, Joaquín M ^b   Lacal, Juan Carlos ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS[4 (N METHYLANILINO)PYRIDINIUM]; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[4 (3,5 DICHLORO N METHYLANILINO)PYRIDINIUM]; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[4 (4 CHLORO N METHYLANILINO)PYRIDINIUM]; 1,1' (CYCLOPROPANE 1,2 DIYLMETHYLENE)BIS[4 (3,5 DIHCLORO N METHYLANILINO)PYRIDINIUM]; CHOLINE KINASE; PYRIDINIUM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL PROLIFERATION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; ELECTRON TRANSPORT; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BENZENE DERIVATIVES; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CHOLINE KINASE; CYCLOPROPANES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PYRIDINIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 6344278007     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0496537     Document Type: Article

References (28)

1. Bertram, J. S. The molecular biology of cancer. Mol. Aspects Med. 2000, 21, 167-223.
2. Sherr, C. J, McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2, 103-112.
3. Blume-Jense, P.; Hunter, T. Oncogenic kinase signalling. Nature 2001, 411, 355-365.
4. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 700, 57-70.
5. Hahn, W. C.; Weinberg, R. A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2002, 2, 331-341.
6. Carnero, A. Targeting the cell cycle for cancer therapy. Br. J. Cancer 2002, 87, 129-133.
7. Cuadrado, A.; Carnero, A.; Dolfi, F.; Jimenez, B.; Lacal, J. C. Phosphorylcholine: A novel second messenger essential for mitogenic activity of growth factor. Oncogene 1993, 8, 2959-2963.
8. Jimenez, B.; del Peso, L.; Montaner, S.; Esteve, P.; Lacal, J. C. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-Kinases in growth factors-induced mitogenic stimulation. J. Cell. Biochem. 1995, 57, 141-149.
9. Ramirez de Molina, A.; Peñalva, V.; Lucas, L.; Lacal, J. C. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 2002, 21, 937-946.
10. Lacal, J. C. Choline Kinase: A novel target for antitumor drugs. Idrugs 2001, 4, 419-426.
11. Hernandez-Alcoceba, R.; Saniger, L.; Nuñez, M. C.; Khaless, F.; Gallo, M. A.; Espinosa, A.; Lacal, J. C. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997, 15, 2289-2301.
12. Hernández-Alcoceba, R.; Fernández, F.; Lacal, J. C. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res. 1999, 59, 3112-3118.
13. Cannon, J. G. Structure-activity aspects of hemicholinium-3 (HC-3) and its analogues and congeners. Med. Res. Rev. 1994, 14, 505-531.
14. Cannon, J. G.; Lee, T.M-L.; Nyalda, A. M.; Bhattacharyya, B.; Long, J. P. Structure-activity relationship studies in the hemicholinium ('CHC-3') series. Drug Des. Delivery 1987, 1, 209-218.
15. Campos, J.; Núñez, M. C.; Rodríguez, V.; Gallo, M. A.; Espinosa, A. QSAR of 1,1′-(1,2-ethylenebisbenzyl)bis(4- substitutedpyridinium) dibromides as choline kinase inhibitors: a different approach for antiproliferative drug design. Bioorg. Med. Chem. Lett. 2000, 10, 767-770.
16. Campos, J.; Núñez, M. C.; Rodríguez, V.; Entrena, A.; Hernández-Alcoceba, R.; Fernández, F.; Lacal, J. C.; Gallo, M. Á.; Espinosa, A. LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase. Eur. J. Med. Chem. 2001, 36, 215-225.
17. Campos, J.; Núñez, M. C.; Sánchez, R. M.; Gómez-Vidal, J. A.; Rodríguez-González, A.; Báñez, M.; Gallo, M. Á.; Lacal, J. C.; Espinosa, A. Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds. Bioorg. Med. Chem. 2002, 10, 2215-2231.
18. Conejo-García, A.; Campos, J.; Sánchez, R. M.; Rodríguez-González, A.; Lacal, J. C.; Gallo, M. A.; Espinosa, A. Choline kinase inhibitory effect and antiproliferative activity of new 1,1′,1″-(benzene-1,3,5-triylmethylene)tris{4-[(disubstituted) aminolpyridinium} tribromides. Eur. J. Med. Chem. 2003, 38, 109-116.
19. Campos, J.; Núñez, M. C.; Conejo-García, A.; Sánchez-Martín, R. M.; Hernández-Alcoceba, R.; Rodríguez-González, A.; Lacal, J. C.; Gallo, M. Á.; Espinosa, A. QSAR-derived choline kinase inhibitors: How rational can antiproliferative drug design be? Curr. Med. Chem. 2003, 10, 1241-1253.
20. Conejo-García, A.; Campos, J.; Sánchez-Martín, R. M.; Gallo, M. A.; Espinosa, A. Bispyridinium Cyclophanes: Novel Templates for Human Choline Kinase Inhibitors. J. Med. Chem. 2003, 46, 3754-3757.
21. Qin, D.; Sullivan, R.; Berkowitz, W. F.; Bittman, R.; Rotenberg, S. A. Inhibition of Protein Kinase Cα by Dequalinium Analogues: Dependence on Linker Length and Geometry. J. Med. Chem. 2000, 43, 1413-1417.
22. Tao, B.; Huang, T. L.; Zhang, Q.; Jackson, L.; Queener, S. F.; Donkor, I. O. Synthesis and anti-Pneumocystis carinii activity of conformationally restricted analogues of pentamidine. Eur. J. Med. Chem. 1999, 34, 531-538.
23. Neset, S.; Hope, H.; Undheim, K. Stereoselective Synthesis of Cyclopropane-1,2-bis(Glycine) Derivatives. Tetrahedron 1997, 53, 10459-10470.
24. Wenner, W. Bis(bromomethyl)compounds. J. Org. Chem. 1952, 17, 523-528.
25. Szendey, G. L.; Munnes, S. Konstitution und eigenschaften des biphenylen-(4,4′)-bis-[methylatropiniumbromids], einer biquartären atropinverbindung. (Constitution and properties of biphenylene-(4,4′)- bis[methylatropinium] bromide, a bisquaternary atropine compound.) Chem. Ber. 1961, 94, 38-42.
26. Staab, H. A.; Haenel, M. Synthesen won [2.2](4,4′)biphenylophan, [2.2](2,7)phenanthrenophan und [2](4,4′)biphenylo[2](2, T)-phenanthrenophan. Chem. Ber. 1973, 106, 2190-2202.
27. Schnall, S.; Macdonald, J. S. in: Macdonald, J. S., Haller, D. G., Mayer, R. J., Eds.; Manual of Oncologic Therapeutics; J. B. Lippincott Co.: Philadelphia, 1995; pp 170-184.
28. Rodríguez-González A.; Ramírez de Molina A, Fernández F.; Ramos M. A.; Nuñez, M. C.; Campos, J. Mand Lacai J. C. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003, 22, 8803-8812.